Ultrasound technology developer Misonix said that results for the firm's Sonatherm 600 high-intensity focused ultrasound (HIFU) clinical trials for kidney cancer were promising.
The Farmingdale, NY-based Misonix reported that Dr. Michael Marberger, chairman and professor of the department of urology at the University of Vienna Medical School in Austria said that procedures in the trial were successfully completed, with positive ablation effect noted on cancer cells in tumors within human kidneys.
By AuntMinnie.com staff writers
March 22, 2007
Related Reading
Misonix, Partnermed sign Scandinavian HIFU deal, March 6, 2007
Sonora, MDT ink joint development deal, February 20, 2007
Constantine leaves Misonix, January 9, 2007
Misonix gets new credit facility, January 4, 2007
Misonix lands Hungarian HIFU order, November 16, 2006
Copyright © 2007 AuntMinnie.com